Protagonist Therapeutics, Inc.
PTGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4,236 | $3,510 | $3,045 | $2,406 |
| - Cash | $114 | $169 | $140 | $97 |
| + Debt | $11 | $11 | $11 | $11 |
| Enterprise Value | $4,133 | $3,353 | $2,917 | $2,319 |
| Revenue | $5 | $6 | $28 | $171 |
| % Growth | -15% | -80.4% | -83.4% | – |
| Gross Profit | $5 | $6 | $28 | $171 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$39 | -$42 | -$19 | $127 |
| % Margin | -827.2% | -752.6% | -67.3% | 74.6% |
| Net Income | -$39 | -$35 | -$12 | $132 |
| % Margin | -834.9% | -627% | -41.2% | 77.2% |
| EPS Diluted | -0.62 | -0.55 | -0.19 | 1.98 |
| % Growth | -12.7% | -189.5% | -109.6% | – |
| Operating Cash Flow | -$2 | -$29 | $125 | -$29 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$2 | -$30 | $125 | -$29 |